Researchers reported on the contribution of trained immune responses to protection against SARS-CoV-2 infections and future pandemics.
Antios reportedly shut down; Clene’s long-term ALS data; Keytruda, Lenvima’s lung cancer failures
Plus, Valneva signs US contract for Ixiaro, and Pierre Fabre inks a cancer deal with Vernalis. Hepatitis B startup Antios Therapeutics shuts down — report